Rigel Pharmaceuticals Long Term Debt

Rigel Pharmaceuticals (RIGL) currently reports a long-term debt of $15M as of March 2026. That compares with $46M in the prior-year period — down 66.8% year over year. Use the charts on this page to explore Rigel Pharmaceuticals's long-term debt history and peer comparisons.

Rigel Pharmaceuticals's long-term debt decreased from $46M to $15M — a 66.8% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Rigel Pharmaceuticals reported $15M in long-term debt as of March 2026. That compares with $46M in the prior-year period — down 66.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $15M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Rigel Pharmaceuticals, and consider following RIGL for alerts when major investors trade the stock.

Rigel Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $15M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RIGL with unrelated industries.